Our corporate sustainability and responsibility

Our ambition to improve the health of people worldwide is the driving force behind our work in advancing the development of novel medicines. As part of this effort, BioNTech aims to address high and unmet global medical needs, including diseases with pandemic potential – mostly affecting low- and lower middle-income countries.

Facilitating access to vaccines is an important step towards vaccine equity. Our vision is for vaccines to be produced regionally, on highly flexible medical and technological platforms, with local participation and engagement to address a region’s priority diseases. Our four principles – transparency, integrity, respect for the environment and human rights – and the UN SDGs guide us in implementing this vision.

For more information, please refer to chapter 2.0, “Our Responsibility" in our Sustainability Report 2025.

We base our business activities on sound principles: We require our employees to act lawfully, ethically and responsibly and support them in this regard through internal training.  BioNTech respects human rights and is committed to upholding social and environmental standards along its value chain. As a research-focused biotechnology company, ensuring information security and patient privacy is of critical importance to us. From the research and clinical trial phases to approved and distributed products, BioNTech makes the well-being of patients its highest priority.  We also strive to achieve excellent research results while safeguarding individual animal welfare. When engaging with political stakeholders and governments, we aim to foster a constructive dialogue to further advance our vision.
 

For further information, please refer to the chapter "4.0 Responsible Governance" in our Sustainability Report 2025.

At the end of 2025, over 8,000 employees from more than 110 nations worked at our sites worldwide. Ensuring an innovation fostering corporate culture and successfully managing a global workforce depends on well-functioning, integrated structures. Our global Human Resources department is dedicated to attracting, developing, and retaining top talent while fostering an environment where everyone feels respected, valued, and empowered to reach their full potential. HR plays a vital role in driving organizational transformation, ensuring our workforce adapts responsibly to evolving business needs.

At BioNTech, we believe the strength of our diverse teams lies in their unique perspectives and experiences, driving innovation and breakthroughs. Our inclusive culture reflects the diversity of the communities we serve. We strive to ensure everyone thrives based on merit, regardless of gender, identity, political opinion, religion, nationality, ethnicity, age, orientation, marital status, disability, or health. Discrimination, favoritism, or harassment are not tolerated, as regulated by law and Company policies, including our Code of Ethics & Business Integrity.

We foster a culture of continuous learning and prioritize high occupational safety standards as a foundation of our work.

Further information can be found in the chapter "6.0 Attractive Employer" in our Sustainability Report 2025.

As a research-focused and commercial biotechnology company, our work has an impact on the environment: manufacturing processes, R&D activities and the operation of our infrastructure lead to energy requirements, consumption of raw and auxiliary materials and the generation of waste.

BioNTech continuously develops its global environmental management in the areas of wastewater, waste and energy management. Climate protection is the focus of our environmental management: We have developed a climate strategy with near-term science-based emissions reduction targets. In January 2024, the targets have been approved by the Science Based Targets initiative (SBTi) as follows:
 

·       BioNTech commits to reduce absolute scope 1 and 2 GHG emissions by 42% by 2030 from a 2021 base year.

·       BioNTech commits that 72% of its suppliers by emissions covering purchased goods and services, capital goods and upstream transportation and distribution, will have science-based

targets by 2027.

This validation underlines that our scope 1 and scope 2 climate targets are ambitious and in alignment with the United Nation’s Paris Climate Agreement to limit global warming to 1.5 degrees Celsius above pre-industrial levels.

To achieve our direct greenhouse gas emissions reduction targets (Scope 1 and Scope 2), a dedicated decarbonization department was established in 2022. Since then, we have continued to implement measures, including planning and setting yearly reduction targets for our operational sites, monitoring progress, and executing decarbonization initiatives to support our pathway toward the 2030 target. In 2025, the Management Board approved an extended roadmap for achieving our near-term targets, along with an interim target for 2028 that aligns with SBTi targets for Scope 1 and Scope 2. Additionally, we continued to advance efforts toward meeting our SBTi supplier engagement target commitment for Scope 3 emissions. Climate risk management - addressing both transition risks and physical risks as outlined by the Task Force on Climate-Related Financial Disclosures (TCFD) - was also established in 2022 and will continue to be developed. Further information on our environmental management can be found in section "5.0 Environmental & Climate Protection" in our Sustainability Report 2025.

As a company, BioNTech is actively engaged socially. Our corporate citizenship concept serves as the framework guiding all of our activities, whether that be monetary or in-kind charitable donations, corporate volunteering, or sponsorships. The concept addresses three different focus topics: Regional causes, health-related impact and exceptional causes.

Read the chapter "3.0 Corporate Citizenship" in our Sustainability Report 2025 to find out how we shape our social commitment sustainably and in line with our corporate values.